Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer

KRAS-driven lung cancers frequently inactivate TP53 and/or STK11/LKB1, defining tumor subclasses with emerging clinical relevance. Specifically, KRAS-LKB1 (KL) mutant lung cancers are particularly aggressive, lack PD-L1, and respond poorly to immune checkpoint blockade (ICB). The mechanistic basis f...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Discov
Autors principals: Kitajima, Shunsuke, Ivanova, Elena, Guo, Sujuan, Yoshida, Ryohei, Campisi, Marco, Sundararaman, Shriram K., Tange, Shoichiro, Mitsuishi, Yoichiro, Thai, Tran C., Masuda, Sayuri, Piel, Brandon P., Sholl, Lynette M., Kirschmeier, Paul T., Paweletz, Cloud P., Watanabe, Hideo, Yajima, Mamiko, Barbie, David A.
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6328329/
https://ncbi.nlm.nih.gov/pubmed/30297358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-18-0689
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars